Insulin glargine-yfgn injection is indicated to improve glycemic control in adult and paediatric
patients with diabetes mellitus

Biocon Biologics announced the expansion of its strategic collaboration with Civica (Civica) to include a new Insulin Glargine medicine that will benefit patients in the US by increasing the supply of high-quality, affordable insulins.

The multi-year transformational agreement between Biocon Biologics and Civica creates an
exclusive distributorship arrangement where Biocon Biologics will manufacture and supply Insulin
Glargine medicine to Civica, and Civica will commercialize under Biocon Biologics’ existing
marketing approval (a private label agreement). Civica will distribute, promote, and sell the
medicine in the United States under a separate Civica label and trade dress, and in California, the
product will carry the CalRx brand. Biocon Biologics will continue to directly commercialize Biocon
Biologics’ own Insulin Glargine-yfgn medicine, which was approved by the US Food and Drug
Administration (FDA) in July 2021 as the first interchangeable biosimilar.

Shreehas Tambe, CEO and Managing Director, Biocon Biologics, said, “Biocon Biologics is
committed to expanding access to affordable, high-quality insulins in the US and globally. By
extending our collaboration with Civica, Inc. to include Insulin Glargine, we are building on our
differentiated approach to serving and enhancing patient access by retaining our direct
commercialization and through this strategic partnership. This collaboration enables us to reach
underserved populations through new channels in direct alignment with our mission.”

Ned McCoy, President and Chief Executive Officer, Civica, said, “We are pleased to expand our
partnership with Biocon Biologics, which helps us achieve a significant milestone in our insulin initiative. Today’s announcement allows us to realise our goal of bringing insulin to people who
need it at a transparent low price.”